GlaxoSmithKline agreed to buy Nuvalent for about $10.6 billion to expand its late-stage lung-cancer franchise with two precision oncology programs under FDA review. The deal brings ROS1 inhibitor zidesamtinib (NVL-520) and ALK inhibitor neladalkib (NVL-655), both supported by Breakthrough Therapy and Orphan Drug designations, with FDA decision targets set for September and November, respectively. The acquisition also includes NVL-330, a HER2 inhibitor in early Phase I development for HER2-altered NSCLC. GSK said the assets are designed to address efficacy and tolerability gaps versus existing ROS1 and ALK therapies, including resistance driven by “solvent front” mutations, and to maintain activity in the CNS. For investors, the timing matters: GSK plans to use the new lung assets to build growth as approvals are expected later this year, while also adding a platform of additional preclinical programs from Nuvalent. The multi-product structure underscores GSK’s bolt-on strategy as it rotates toward differentiated oncology indications.